DMR Logo.png
BioHacking Market Is Expected To Reach A Revenue Of USD 159.1 Bn By 2033, at 20.2% CAGR: Dimension Market Research
02 juil. 2024 11h13 HE | Dimension Market Research
New York, July 02, 2024 (GLOBE NEWSWIRE) -- Overview: The Global BioHacking Market size is expected to reach USD 30.3 billion by 2024 and is further anticipated to reach USD 159.1 billion by...
Mordor Intelligence Logo_Comp.png
Bioplastics Market Revenues to Reach a Volume of 3,951.43 kilotons by 2028 - Market Volume, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
14 juil. 2023 09h30 HE | Mordor Intelligence
Hyderabad, July 14, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Bioplastics Market Report (2023-2028)," the market volume is estimated at 1,783.16 kilotons in 2023. It...
SAB_Logo.png
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
09 août 2022 16h30 HE | SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
Q-Med Quarterly Report January - March 2003
12 mai 2003 10h15 HE | Q-Med
UPPSALA, Sweden, May 12, 2003 (PRIMEZONE) -- Q-Med: Sales increased by 24 percent to SEK 141.3 (113.7) million. Adjusted for changes in exchange rates, sales increased by 33 percent. On a rolling...
Actelion Announces Fourth Quarter and Full-year 2002 Financial Results Above Expectations
18 févr. 2003 01h54 HE | Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Feb. 18, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) today announced its financial results for the year 2002. With operating revenues more than...
Q-Med: Report on Operations 2002
10 févr. 2003 06h45 HE | Q-Med
UPPSALA, Sweden, Feb. 10, 2003 (PRIMEZONE) -- Q-Med (Stockholm:QMED): -- Sales increased during the year by 36 percent to SEK 517.8 (380.2) million. During the fourth quarter turnover...
Tripep: Preliminary Year-End Report for 2002
31 janv. 2003 03h52 HE | Tripep
HUDDINGE, Sweden, Jan. 31, 2003 (PRIMEZONE) -- Tripep AB (publ): -- A new Board of Directors was elected at the extraordinary meeting of shareholders held on September 17, 2002. The new...
Crucell Reports 2002 Annual Results
27 janv. 2003 02h29 HE | Crucell N.V.
LEIDEN, The Netherlands, Jan. 27, 2003 (PRIMEZONE) -- Crucell N.V. (Nasdaq:CRXL) today announced its 2002 financial results. Total revenues for the year ended December 31, 2002 are $9.6 million...
GeneMedix plc: Quarter 3 Results for the Nine Months to August 31, 2002
19 nov. 2002 04h20 HE | GeneMedix plc
SUFFOLK, U.K., Nov. 19, 2002 (PRIMEZONE) -- GeneMedix plc (LSE:GMX) ("GeneMedix" or "the Company"), the U.K. generic biopharmaceutical company with operations in Europe and Asia and with joint London...
Innogenetics Reports Profitable Diagnostics Activities and Increased R&D Investments for the First Nine Months of 2002
15 nov. 2002 04h09 HE | Innogenetics
GENT, Belgium, Nov. 15, 2002 (PRIMEZONE) -- Innogenetics (Other OTC:INGTF) today announced its results for the first nine months ending September 30, 2002. Highlights -- Diagnostics Division...